Table 3.
Two-way ANOVA | Type of treatment |
Imaging modality |
p interaction | ||||
---|---|---|---|---|---|---|---|
DEB + BMS (n = 28) | DES (n = 28) | p value | OCT (n = 16) | IVUS (n = 40) | p value | ||
Neointimal thickness, μm | 125.99 ± 107.69 | 68.73 ± 91.16 | 0.025 | 138.26 ± 128.59 | 81.00 ± 87.41 | 0.042 | |
Neointimal hyperplasia area, mm2 | 1.02 ± 0.99 | 0.46 ± 0.69 | 0.011 | 1.02 ± 1.29 | 0.63 ± 0.66 | 0.103 | 0.006 |
Neointimal hyperplasia volume, mm3 | 20.30 ± 24.15 | 11.28 ± 18.75 | 0.105 | 20.93 ± 31.60 | 13.74 ± 16.65 | 0.240 | 0.011 |
Volume obstruction, % | 14.90 ± 15.36 | 7.03 ± 11.39 | 0.025 | 14.91 ± 18.96 | 9.38 ± 11.32 | 0.150 | 0.014 |
Mean lumen area, mm2 | |||||||
Post | 7.36 ± 2.29 | 6.79 ± 2.05 | 0.334 | 7.67 ± 1.90 | 6.84 ± 2.25 | 0.195 | |
9-Month follow-up | 6.53 ± 2.45 | 6.59 ± 2.22 | 0.918 | 6.43 ± 2.18 | 6.61 ± 2.40 | 0.785 | |
Post-9-month follow-up | 0.83 ± 1.11 | 0.20 ± 0.81 | 0.009 | 1.24 ± 1.15 | 0.22 ± 0.79 | < 0.001 | |
Minimum lumen area, mm2 | |||||||
Post | 6.09 ± 2.16 | 5.56 ± 1.89 | 0.337 | 6.25 ± 1.56 | 5.66 ± 2.18 | 0.329 | |
9-Month follow-up | 5.21 ± 2.32 | 5.42 ± 2.08 | 0.706 | 5.03 ± 2.00 | 5.43 ± 2.27 | 0.533 | |
Post-9-month follow-up | 0.89 ± 1.35 | 0.14 ± 0.93 | 0.013 | 1.22 ± 1.39 | 0.23 ± 1.01 | 0.003 | |
Lumen volume, mm3 | |||||||
Post | 126.95 ± 50.17 | 154.63 ± 66.89 | 0.804 | 156.63 ± 61.61 | 134.45 ± 59.25 | 0.208 | |
9-Month follow-up | 116.00 ± 55.38 | 153.74 ± 73.45 | 0.034 | 129.06 ± 60.76 | 137.19 ± 70.22 | 0.677 | |
Post-9-month follow-up | 10.95 ± 35.93 | 0.89 ± 41.48 | 0.308 | 27.57 ± 28.70 | –2.74 ± 39.18 | 0.007 | |
Mean stent area, mm2 | |||||||
Post | 7.47 ± 2.34 | 6.70 ± 1.98 | 0.191 | 7.14 ± 1.84 | 6.95 ± 2.31 | 0.482 | |
9-Month follow-up | 7.53 ± 2.46 | 6.98 ± 2.06 | 0.374 | 7.45 ± 1.89 | 7.17 ± 2.42 | 0.687 | |
Post-9-month follow-up | –0.06 ± 0.33 | –0.28 ± 0.32 | 0.012 | –0.04 ± 0.33 | –0.22 ± 0.34 | 0.060 | |
Minimum stent area, mm2 | |||||||
Post | 6.28 ± 2.22 | 5.52 ± 1.80 | 0.170 | 6.12 ± 1.53 | 5.81 ± 2.22 | 0.605 | |
9-Month follow-up | 6.48 ± 2.27 | 5.85 ± 1.92 | 0.277 | 6.23 ± 1.69 | 6.14 ± 2.27 | 0.885 | |
Post-9-month follow-up | –0.20 ± 0.45 | –0.33 ± 0.48 | 0.275 | –0.11 ± 0.61 | –0.33 ± 0.61 | 0.104 | |
Stent volume, mm3 | |||||||
Post | 135.74 ± 51.95 | 159.70 ± 65.61 | 0.139 | 150.81 ± 58.96 | 146.49 ± 60.92 | 0.807 | |
9-Month follow-up | 139.66 ± 64.05 | 167.18 ± 73.60 | 0.145 | 149.99 ± 66.35 | 154.79 ± 71.85 | 0.817 | |
Post-9-month follow-up | –3.92 ± 22.55 | –7.48 ± 32.66 | 0.636 | 0.82 ± 22.07 | –8.31 ± 29.72 | 0.276 |
Values are presented as mean ± SD.
ANOVA, analysis of variance; DEB, drug-eluting balloon; BMS, bare metal stent; DES, drug-eluting stent; OCT, optical coherence tomography; IVUS, intravascular ultrasonography.